Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from EKF Diagnostics Holdings ( (GB:EKF) ) is now available.
EKF Diagnostics Holdings has reported its full-year results for 2024, highlighting a 9.2% growth in adjusted EBITDA and stronger than expected cash generation. The company has focused on higher margin product ranges and core operations, while winding down non-core and low margin product lines. This strategic shift has resulted in improved gross margins and a significant strengthening of its balance sheet. EKF has also announced a five-year strategic development plan aimed at accelerating growth, with a focus on reinvesting in its core business divisions to drive organic growth and margin improvement. The company is considering various options for utilizing its strong cash generation to deliver further value to shareholders.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is an AIM-listed global diagnostics company specializing in Point-of-Care analyzers, particularly in Hematology and Diabetes, and Life Sciences services, which include the manufacture of enzymes and custom products for diagnostic, food, and industrial applications. The company operates five manufacturing sites across the US and Germany and sells its products in over 120 countries worldwide.
YTD Price Performance: -24.07%
Average Trading Volume: 399,122
Technical Sentiment Signal: Buy
Current Market Cap: £93.01M
See more data about EKF stock on TipRanks’ Stock Analysis page.